ArticleSurgical neurology international2026
Outcomes in spinal ependymoma: A retrospective analysis of 38 patients.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal ependymomas are rare central nervous system tumors with an incidence of approximately 1 in 100,000. They comprise 2-6% of CNS tumors, and up to 60% of intramedullary tumors. In this study, we retrospectively analyzed prognostic factors affecting progression-free survival (PFS) and postoperative outcomes for 38 patients. Methods: Clinical and histological data were collected for 38 patients treated at a single neurosurgical center (2012-2021). Data included presenting symptoms, tumor grade and location, type of management (gross total resection [GTR], subtotal resection [STR], or conservative), use of adjuvant therapy, and outcomes such as PFS and functional status. Results: Patients averaged 55 years of age, and there was an equal gender distribution. Tumors most commonly occurred in the lumbar spine (58%), and 47% were classified as the World Health Organization Grade II. Pain was the most frequent presenting symptom (79%). GTR was achieved in 58% of patients, STR in 36%, and 13% were managed conservatively. GTR significantly reduced tumor progression compared to STR ( Conclusion: This study underscores the importance of GTR in reducing progression while preserving functional outcomes in spinal ependymoma. Adjuvant therapy remains controversial, with limited evidence supporting its benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.